Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, positioning the company for ...

New research presented at ASCO GI positions both agents as potent therapeutic options, with potential to redefine standard ...

Researchers will use a quantitative continuous scoring platform to measure patients' tumors for TROP2 expression in the trial.

Furthermore, a near-doubling of 12-month survival was also achieved with the elraglusib regimen vs GnP alone (44.4% vs 22.3%) ...

Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.

The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...

Erasca reported favorable safety and tolerability with no dose-limiting toxicities and predominantly low-grade adverse events ...

A research team from the Yunnan Observatories of the Chinese Academy of Sciences (CAS), in collaboration with domestic and ...

Amgen is hoping to gain a slice of the obesity market with MariTide, which it claims has a differentiated profile to other ...

First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment - ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published today in Nature Medicine, the novel monoclonal antibody linavonkibart demonstrated the ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...